Viba Therapeutics

 Humanized monoclonal antibody (mAb) therapeutics for the treatment of  solid tumors, licensed exclusively from the University of Texas MD  Anderson Cancer Center.  Viba mAbs target a validated pathway which  initiates and drives the progression and metastasis of numerous  malignancies, including breast, pancreatic, ovarian, prostate, and  colorectal cancer, and effect substantial increases in overall survival  and tumor regression as single-agent therapy in highly-stringent animal  models of advanced cancer which is refractory to standard-of-care  treatment.  

Centaurus Therapeutics

 Small molecule inhibitors of a highly-validated target in the ceramide  biosynthesis pathway, for the treatment of NASH, dyslipidemia, type 2  diabetes, and other metabolic diseases.  Inhibition of this target by a  small molecule tool compound in animals reverses insulin resistance and  completely cures fatty liver disease. 

Celmune Therapeutics

 Small molecule immuno-oncology agents for the treatment of solid tumors  and hematologic malignancies.  Celmune compounds target an immune cell  population and pathway which contribute to a highly immunosuppressive  tumor microenvironment that enables cancer cells to evade detection by  the immune system. Tool compounds targeting this pathway effect  substantial tumor regression and decreased metastasis in  highly-stringent tumor models in animals having intact immune systems.